Compare · PM vs PXMD
PM vs PXMD
Side-by-side comparison of Philip Morris International Inc (PM) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PM and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM carries a market cap of $161.16B.
- PM has hit the wire 11 times in the past 4 weeks while PXMD has been quiet.
- PM has more recent analyst coverage (25 ratings vs 0 for PXMD).
- Company
- Philip Morris International Inc
- PaxMedica Inc.
- Price
- -
- -
- Market cap
- $161.16B
- -
- 1M return
- -0.86%
- -
- 1Y return
- -2.95%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Latest PM
- SEC Form 10-Q filed by Philip Morris International Inc
- Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Philip Morris International Reports 2026 First-Quarter Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
- IQOS and Devialet Introduce "Soundsorial Design" Collaboration
- Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product
- PMI U.S. Calls for Science‑Based Policy and Credible, Open Dialogue to Accelerate America's Smoke‑Free Future
- One in Three Cigarettes in the Region of The Americas in 2025 Is Illicit, New Study Finds
- Philip Morris International to Host Webcast of 2026 First-Quarter Results
- New "Forgotten Smoker" White Paper from PMI U.S. Warns That America Didn't End Smoking; It Just Moved On--and 8 in 10 Americans Surveyed Demand a Better Approach
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection